On April 19, Hengrui announced its 2020 annual report.
The annual operating income was 27.
735 billion yuan, a year-on-year increase of 19.
09%; the net profit attributable to shareholders of listed companies was 6.
328 billion yuan, a simultaneous increase of 18.
78%; R&D expenses were 4.
989 billion yuan, a year-on-year increase 28.
04%, accounting for 17.
99% of operating income.
Hengrui Medicine's revenue, net profit and R&D investment in the past 10 years (unit: 100 million yuan)
Hengrui Medicine's R&D investment growth trend in the past 10 years
Hengrui Pharmaceutical's main business involves drug R&D, production and sales, and its main products cover many fields such as anti-tumor drugs.
Among Hengrui's revenue of RMB 100 million in 2020, oncology drugs contributed 15.
268 billion RMB.
The main driving factors for Hengrui's revenue growth are the following: sales of oncology drugs increased by 44.
37% compared with last year, sales of contrast agent products increased by 12.
4% compared with last year, and anesthesia products decreased by 16.
Cardiovascular and anti-inflammatory income are not listed separately.
Performance of Hengrui's major product business segments (100 million yuan)
R&D expenses increased by 28%, innovative drugs and generic drugs go hand in hand
Up to now, Hengrui's innovative drugs are irecoxib, apatinib mesylate, thiopefigrastim, pirotinib maleate, carrelizumab, remazolam tosylate and fluorophore Zopali is launched.
At present, nearly 20 projects have been approved to carry out global multi-center or regional clinical research.
Among them, karelizumab combined with apatinib, fluzoparib and other products have carried out phase III clinical trials in international multi-centers.
During the reporting period, the cumulative R&D investment was 4.
989 billion yuan, an increase of 28.
04% over the same period of the previous year, which strongly supported project R&D and innovation development.
Investment in Hengrui's main R&D projects (unit: ten thousand yuan)
Basic situation of Hengrui's main R&D projects
The status of Hengrui's products submitted to regulatory authorities for approval during the reporting period
In terms of consistency evaluation, Hengrui has 9 products passed the consistency evaluation in 2020.
Up to now, a total of 30 varieties have been evaluated, 19 of which have been included in the first 4 batches of centralized procurement.
A total of 12 won the bid, and the winning rate reached 63%.
In addition, there are 5 products that have been reviewed are the fifth batch of collected varieties, including 4 injections and 1 oral preparation, namely glycopyrrolate injection, docetaxel injection, and cisatracurium besilate Injection, ropivacaine injection and dutasteride soft capsules.
Hengrui passed the consistency evaluation of the number of varieties and the bidding situation of centralized procurement
A number of innovative drugs have started international multi-center phase III clinical trials
In terms of internationalization, Hengrui will continue to increase the implementation of its internationalization strategy in 2020 and actively expand overseas markets.
The establishment of a European clinical center in Basel, Switzerland to further improve the global innovation system will help accelerate the development of innovative drugs including cancer treatment.
In terms of the internationalization of generic drugs, dexmedetomidine hydrochloride and sodium chloride injection was approved for sale in the United States.
Hengrui has been approved for 20 preparations including injections, oral preparations and inhaled anesthetics in Europe, America and Japan.
1 A preparation product obtained provisional approval in the United States; during the reporting period, the company submitted four API registration applications to the US FDA and one listing application to Australia.
In terms of the internationalization of innovative drugs, a number of products have been approved to conduct global multi-center or regional clinical studies.
Among them, karelizumab combined with apatinib, fluzoparib and other products have launched phase III clinical trials in international multi-centers .
In terms of innovative overseas export, during the reporting period, the company licensed Carrelizumab, Pirrotinib, and SHR-1701 projects to South Korea’s Crystal Genomics, South Korea’s HLB-LS, and South Korea’s East Asia Pharmaceuticals, which will further enhance the company’s innovative brand influence Strength and overseas performance.